Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corp’s chief development officer, Tomas Navratil, reported a small tax-related share disposition. On the vesting of previously granted restricted stock units, 396 shares of common stock were withheld by the company at $119.17 per share to cover tax obligations. After this withholding, Navratil directly holds 77,055 shares of common stock, including 42,588 restricted stock units that are granted but not yet vested or delivered.
GLAUKOS Corp President and COO Joseph E. Gilliam reported a Form 4 showing a tax-related share disposition tied to vesting equity awards. On this Form 4, 1,057 shares of common stock were withheld by the company at $119.17 per share to satisfy his tax withholding obligations when restricted stock units granted on March 18, 2021 vested and were delivered.
After this tax-withholding disposition, Gilliam directly owned 91,309 shares of GLAUKOS common stock, which includes 60,661 restricted stock units that have not yet vested or been delivered. This reflects an administrative equity and tax event rather than an open-market stock sale.
GLAUKOS Corp director Aimee S. Weisner reported multiple equity transactions in company stock. She exercised a stock option for 15,000 shares of common stock at an exercise price of $24.69 per share, then reported open-market sales totaling 15,000 shares at weighted average prices between $115.69 and $118.56 across several trade blocks. She also reported bona fide gifts of 980 shares from her direct holdings and 980 shares transferred to the Saeman-Weisner Family Trust. After these transactions, she directly owned 18,806 shares and indirectly owned 29,505 shares through the Saeman-Weisner Family Trust, which includes 2,731 restricted stock units noted in the footnotes.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders and retinal disease. Its core products include the iStent micro‑scale glaucoma devices, iDose TR long‑duration intracameral implant approved in December 2023, and Photrexa/iLink corneal cross‑linking therapies.
The FDA approved Epioxa iLink epi‑on for keratoconus in October 2025, with commercial launch planned in the first half of 2026. In 2025, about 83% of net sales came from glaucoma products (iStent family, iDose TR and accessories) and 17% from iLink therapies. The company is advancing multiple platforms, including iLution transdermal creams and Retinal XR sustained‑release intravitreal drugs, and invests heavily in R&D and international expansion.
Key risks highlighted include dependence on successful commercialization of iDose TR and Epioxa, exposure to macroeconomic and geopolitical volatility, manufacturing and supply disruptions, ongoing operating losses since inception, complex global regulatory and reimbursement regimes, cybersecurity and data‑privacy obligations, and intense competition from larger ophthalmic device and drug companies.
Glaukos Corporation reported record results for the fourth quarter and full year 2025, driven by strong uptake of its glaucoma and corneal therapies. Fourth quarter net sales were $143.1 million, up 36% year over year, while full-year 2025 net sales reached $507.4 million, an increase of 32%.
Despite this growth, Glaukos posted a 2025 GAAP net loss of $187.7 million (or $3.28 per share), widened largely by a one-time, non‑cash impairment charge of $112.9 million tied to an acquired intangible asset from the Avedro acquisition as Photrexa transitions to Epioxa. On a non‑GAAP basis, full‑year net loss narrowed to $51.7 million (or $0.90 per share) from $98.3 million in 2024 as operating performance improved.
Non‑GAAP gross margin improved to about 85% in Q4 2025 and 84% for the year. The company ended 2025 with $282.6 million in cash, cash equivalents, short‑term investments and restricted cash and reported no debt. For 2026, Glaukos expects net sales between $600 million and $620 million, reflecting continued momentum from iDose TR and its broader ophthalmic pipeline.
Janus Henderson Group plc reports beneficial ownership of 3,018,787 shares of Glaukos Corp common stock, representing 5.3% of the class as of 12/31/2025. The shares are held across various investment adviser subsidiaries that manage separate client accounts, called Managed Portfolios.
The asset managers exercise investment and voting discretion, but the Managed Portfolios receive all dividends and sale proceeds, and no single portfolio owns more than five percent of Glaukos stock. Janus Henderson certifies the position is held in the ordinary course of business, without any purpose or effect of changing or influencing control of Glaukos.
PRIMECAP Management Company has filed a Schedule 13G reporting beneficial ownership of Glaukos Corporation shares. PRIMECAP reports holding 3,376,928 shares, representing 5.88% of the class as of 12/31/2025. It has sole voting power over 3,374,178 shares and sole dispositive power over 3,376,928 shares.
The firm states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Glaukos. The filing is signed by Deputy Chief Compliance Officer Jorge Antonio Rodriguez on behalf of PRIMECAP Management.
Glaukos chairman and CEO Thomas W. Burns reported an option exercise and related share movements. On February 9, 2026, he exercised 166,000 stock options with a $30.92 exercise price, receiving 166,000 shares of common stock and bringing his directly held common stock to 255,621 shares, including 89,621 restricted stock units that have not yet vested or been delivered.
On February 6, 2026, 67,353 shares were transferred from his direct ownership to the Burns Family Trust, which is reported as indirectly holding 961,285 common shares. Additional indirect holdings are reported through several Burns-related trusts, including 238,107 shares via the Burns Annuity Trust and other irrevocable and charitable remainder trusts.
Wellington Management Group and related entities filed an amended Schedule 13G reporting their holdings in Glaukos Corporation common stock. The Wellington reporting entities collectively report beneficial ownership of 486,824 shares, with no sole voting or dispositive power and all authority shared across entities and clients.
The filing states this represents ownership of five percent or less of Glaukos’ outstanding common stock and that the securities are owned of record by clients of Wellington-managed investment advisers. Wellington certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Glaukos.